Macquarie Group’s Cartesian Therapeutics RNAC Stock Holding History

Macquarie Group’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-329	Closed	-$24K	–	2395
2020 Q1	$24K	Buy	+329	New	+$31.8K	﹤0.01%	1903

Other funds holding RNAC

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

MWNA

Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

PVMCV

Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Macquarie Group's RNAC Position: Q2 2020 in Review

Macquarie Group sold out of Cartesian Therapeutics (RNAC) in Q2 2020, closing a stake of 329 shares — an estimated $24K sold.

Macquarie Group first reported a position in RNAC in Q1 2020 and held it in 1 quarter. The position peaked at $24K in Q1 2020. 81 funds tracked by Wall St. Rank hold RNAC as of Q2 2020.

Macquarie Group reported no remaining Cartesian Therapeutics position as of Q2 2020 after selling out during the quarter.
Macquarie Group sold 329 Cartesian Therapeutics shares in Q2 2020, an estimated $24K.
Macquarie Group first reported a position in Cartesian Therapeutics in Q1 2020 and held it in 1 quarter.
Macquarie Group's Cartesian Therapeutics position peaked at $24K in Q1 2020.
81 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2020.

Based on Macquarie Group's 13F filing for Q2 2020, filed 11 Aug 2020.